Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin.
Cantarovich
D
D
Service d'Immunologie Clinique et Transplantation, Centre Hospitalier, Nantes, France.
Le Mauff
B
B
Hourmant
M
M
Giral
M
M
Denis
M
M
Jacques
Y
Y
Soulillou
J P
JP
D000293:Adolescent; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000209:etiology; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011817:Rabbits / Q000276:immunology; D011897:Random Allocation; D015375:Receptors, Interleukin-2 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007376:Interleukin-2; D015375:Receptors, Interleukin-2